Kilbee will be responsible for driving the portfolio globally including increased emphasis on digital and content
Chris Kilbee appointed Group Director of UBM Pharma Portfolio
Kilbee will be responsible for driving the portfolio globally including increased emphasis on digital and content
Tags
Related posts
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
